Sensible Biotechnologies has announced that it secured $47 million in financing to advance its innovative mRNA technology platform. The announcement was made on October 6, 2026, and includes a Series A investment led by Oxford Science Enterprises (OSE) along with up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union.
The funds will be utilized to develop Sensible’s VECTOR (Versatile Engine for Cell-based Therapeutic Optimization of RNA) platform and enhance clinical-grade manufacturing capabilities. The company aims to expand the applications of mRNA technology beyond vaccines into various therapeutic areas.
Wilson Sonsini Goodrich & Rosati provided advisory services to OSE specifically focused on intellectual property due diligence related to the financing deal. Key members of the Wilson Sonsini team included Lou Lieto, Jeff Seidel, and Inyoung Choi.
This financing represents a significant step for Sensible Biotechnologies as it seeks to scale its unique approach to mRNA medicine development.
